Blueshift Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Blueshift Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.15M	Buy	+1,843	New	+$1.25M	0.27%	55
2025 Q2	–	Sell	-973	Closed	-$617K	–	574
2025 Q1	$617K	Sell	973 -330	-25%	-$227K	0.24%	106
2024 Q4	$928K	Buy	1,303 +964	+284%	+$809K	0.34%	65
2024 Q3	$356K	Buy	+339	New	+$377K	0.09%	246
2023 Q3	–	Sell	-1,400	Closed	-$1.01M	–	396
2023 Q2	$1.01M	Buy	+1,400	New	+$1.08M	0.38%	57
2023 Q1	–	Sell	-330	Closed	-$238K	–	440
2022 Q4	$238K	Buy	+330	New	+$243K	0.11%	268
2022 Q1	–	Sell	-793	Closed	-$501K	–	1082
2021 Q4	$501K	Sell	793 -789	-50%	-$485K	0.04%	475
2021 Q3	$957K	Buy	+1,582	New	+$982K	0.05%	417
2021 Q2	–	Sell	-2,282	Closed	-$1.08M	–	1128
2021 Q1	$1.08M	Buy	+2,282	New	+$1.11M	0.11%	255
2020 Q1	–	Sell	-11,019	Closed	-$4.14M	–	581
2019 Q4	$4.14M	Buy	11,019 +9,389	+576%	+$3.16M	0.47%	27
2019 Q3	$452K	Buy	+1,630	New	+$482K	0.07%	398
2019 Q2	–	Sell	-890	Closed	-$365K	–	928
2019 Q1	$365K	Buy	+890	New	+$366K	0.05%	472

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Blueshift Asset Management's REGN Position: Q2 2026 in Review

Blueshift Asset Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 1,843 shares worth $1.15M. The stake represents 0.27% of the portfolio and ranks #55 among its holdings. This is a return to the name: Blueshift Asset Management previously reported a position in REGN as recently as Q1 2025.

Blueshift Asset Management first reported a position in REGN in Q1 2019 and has held it in 12 quarters since. The position peaked at $4.14M in Q4 2019. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Blueshift Asset Management held 1,843 shares of Regeneron Pharmaceuticals worth $1.15M as of Q2 2026.
Regeneron Pharmaceuticals was a new Blueshift Asset Management position in Q2 2026.
Regeneron Pharmaceuticals made up 0.27% of Blueshift Asset Management's portfolio in Q2 2026, its #55 holding.
Blueshift Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2019 and has held it in 12 quarters since.
Blueshift Asset Management's Regeneron Pharmaceuticals position peaked at $4.14M in Q4 2019.
1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Blueshift Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.